Investigation of the relationship between fatigue with vitamin D, disease stage, anxiety and physical activity level in patients with Parkinson's disease

Year 2024, Volume: 7 Issue: 3, 296 - 300, 27.05.2024

Aysu Yetiş , Mehmet Canlı , Şafak Kuzu , İrem Valamur , Selcen Duran , Burc Esra Sahin , Hikmet Kocaman , Nazım Tolgahan Yıldız , Halil Alkan

https://doi.org/10.32322/jhsm.1457042

Abstract

Aims: The aim of this study was to investigate the relationship between fatigue severity with vitamin D level, disease stage, anxiety and, physical activity level in patients with Parkinson’s disease (PD).
Methods: This study included 66 (male=38, female=28) individuals diagnosed with PD. Fatigue severity was evaluated by the fatique severity scale, vitamin D level by blood test results, anxiety by the Beck Anxiety Inventory (BAI), disease stage by Hoehn-Yahr (HY) staging, and physical activity level by the International Physical Activity Questionnaire (IPAQ-short form).
Results: The study included 66 (male=38, female=28) individuals diagnosed with PD. Fatigue severity was assessed by the fatique severity scale, vitamin D level by blood test results, anxiety by the BAI, disease stage by HY staging, and physical activity level by the IPAQ-short form. In addition, a significant correlation was found between fatigue severity with vitamin D level, anxiety, disease stage, and physical activity level in men, women, and all patients (p<0.05).
Conclusion: In Parkinson’s patients, fatigue may be related to disease stage, anxiety, physical activity level, and vitamin D level. We suggest that these results should be taken into consideration in fatigue coping strategies for patients with PD.

Keywords

fatigue, vitamin D, anxiety, physical activity, Parkinson

Ethical Statement

The ethics committee approval of the study was approved by Muş Alparslan University Scientific Research and Publication Ethics Committee (Approval Number: 5-2024/12).

References

• Hsiu-Chen C, Chiung-Chu C, Jiunn-Woei L, et al. The effects of dual-task in patients with Parkinson’s disease performing cognitive-motor paradigms. J Clin Neurosci. 2020;72:72-78.
• Rajput A, Birdi S. Epidemiology of Parkinson’s disease. Parkinsonism Relat Disord. 1997;3(4):175-186.
• Çakmur R. Parkinson hastalığının epidemiyolojisi ve klinik özellikleri. Türkiye Klin J Neurol. 2003;1(3):15-17.
• Balestrino R, Schapira A. Parkinson disease. Eur J Neurol. 2020; 27(1):27-42.
• Siciliano M, Trojano L, Santangelo G, De Micco R, Tedeschi G, Tessitore A. Fatigue in Parkinson’s disease: a systematic review and meta‐analysis. Mov Disord. 2018;33(11):1712-1723.
• Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurol. 1993;43(10):2016-2016.
• Van Hilten J, Weggeman M, Van der Velde E, Kerkhof G, Van Dijk J, Roos RA. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease. J Neural Transmiss-Parkinson’s Dis Dement Sect. 1993;5(3):235-244.
• Zhang HJ, Zhang JR, Mao CJ, et al. Relationship between 25‐hydroxyvitamin D, bone density, and Parkinson’s disease symptoms. Acta Neurol Scand. 2019;140(4):274-280.
• Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Mov Disord. 2001;16(2):190-196.
• Havlikova E, Rosenberger J, Nagyova I, et al. Clinical and psychosocial factors associated with fatigue in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(3):187-192.
• Alves G, Larsen JP, Emre M, Wentzel‐Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21(8):1123-1130.
• Abe K, Takanashi M, Yanagihara T. Fatigue in patients with Parkinson’s disease. Behav Neurol. 2000;12(3):103-106.
• Fereshtehnejad SM, Hadizadeh H, Farhadi F, Shahidi GA, Delbari A, Lökk J. Reliability and validity of the Persian version of the fatigue severity scale in idiopathic Parkinson’s disease patients. Parkinson’s Dis. 2013;2013:935429.
• Siciliano M, Chiorri C, De Micco R, et al. Fatigue in Parkinson’s disease: Italian validation of the Parkinson fatigue scale and the fatigue severity scale using a Rasch analysis approach. Parkinsonism Relat Disord. 2019;65:105-110.
• Binkley N, Ramamurthy R, Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin. 2010;39(2):287-301.
• Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord. 2004;19(9):1020-1028.
• Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cognit Psychother. 1998;12(2):163.
• Beck AT, Epstein N, Brown G, Steer R. Beck anxiety inventory. J Consult Clin Psychol. 1993;7(3):195-205.
• Saglam M, Arikan H, Savci S, et al. International physical activity questionnaire: reliability and validity of the Turkish version. Percept Motor Skills. 2010;111(1):278-284.
• Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5): 1763-1768.
• Koçer B. Fatigue in patients with Parkinson’s disease: motor and non-motor clinical associations. Ankara Üniv Tıp Fak Mecmuası. 2017;70(3):169-173.
• Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson’s disease–the fatigue severity scale. Eur J Neurol. 2002;9(6):595-600.
• Martinez-Martin P, Catalan MJ, Benito-Leon J, et al. Impact of fatigue in Parkinson’s disease: the Fatigue Impact Scale for Daily Use (D-FIS). Qual Life Res. 2006;15(4):597-606.
• Evatt ML, DeLong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65(10):1348-1352.
• Sleeman I, Aspray T, Lawson R, et al. The role of vitamin D in disease progression in early Parkinson’s disease. J Parkinson’s Dis. 2017;7(4):669-675.
• Moghaddasi M, Mamarabadi M, Aghaii M. Serum 25-hydroxyvitamin D3 concentration in Iranian patients with Parkinson’s disease. Iranian J Neurol. 2013;12(2):56.
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641-1649.
• Elbers R, van Wegen EE, Rochester L, et al. Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson’s disease? Mov Disord. 2009;24(10):1512-1518.
• Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurol. 2004;63(10):1908-1911.
• Allott R, Wells A, Morrison AP, Walker R. Distress in Parkinson’s disease: contributions of disease factors and metacognitive style. Br J Psychiatry. 2005;187(2):182-183.
• Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurol. 2013;80(4):409-416.
• Siciliano M, De Micco R, Trojano L, et al. The psychological correlates of fatigue in Parkinson’s disease: contribution of maladaptive metacognitive beliefs. Parkinsonism Relat Disord. 2021;91:135-138.
• Gołąb-Janowska M, Kotlęga D, Safranow K, Meller A, Budzianowska A, Honczarenko K. Risk factors of fatigue in idiopathic Parkinson’s disease in a Polish population. Parkinson’s Dis. 2016;2016:2835945.
• Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol. 2007;34(7):865-877.
• Hu X, Song X, Li E, et al. Altered resting-state brain activity and connectivity in depressed Parkinson’s disease. PLoS One. 2015; 10(7):e0131133.
• Christiansen CL, Schenkman ML, McFann K, Wolfe P, Kohrt WM. Walking economy in people with Parkinson’s disease. Mov Disord. 2009;24(10):1481-1487.
• Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson’s disease. Neurol. 2003;60(7): 1119-1124.
• Lana RdC, Araujo LNd, Cardoso F, Rodrigues-de-Paula F. Main determinants of physical activity levels in individuals with Parkinson’s disease. Arq Neuropsiquiatr. 2016;74(2):112-116.